Mereo acquired a portfolio of three product candidates from Novartis in July 2015 including setrusumab (BPS-804), acumapimod (BCT-197), and leflutrozole (BGS-649).
Mereo in-licensed alvelestat (MPH-966) from AstraZeneca in October 2017.
OncXerna Mereo out-licensed navicixizumab (OMP-305B83) to OncXerna Therapeutics, Inc. in January 2020.
ultragenyx Mereo entered a collaboration and license agreement with Ultragenyx Pharmaceutical, Inc. for the development and co-commercialisation of setrusumab (BPS-804) in December 2020.